Fig. 6: IDA-Combo predicts strong benefits for combinations of navitoclax and taxanes in EGFR-WT lung cancer. | Nature Communications

Fig. 6: IDA-Combo predicts strong benefits for combinations of navitoclax and taxanes in EGFR-WT lung cancer.

From: Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action

Fig. 6

a An ordered bar plot of the IDA-comboscores predicted using EGFR-WT lung cancer cell lines for combinations of navitoclax with other drugs that have reached late-stage clinical trials. Each bar represents a different combination of navitoclax with another drug. b and c 3-D plots of measured and predicted average cell viabilities at different concentrations of navitoclax and docetaxel b or paclitaxel c. The gray plane represents the lowest average viability achievable with monotherapy. The red arrow represents the difference between the best observed monotherapy effect and the best predicted combination effect, which suggests that the combination therapy will reduce tumor cell viability below what is achievable with monotherapy alone. Source data are provided as a Source Data file.

Back to article page